Ticker Details
Arbutus Biopharma Corporation Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
IPO Date:	October 31, 2008
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$840.56M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.12 | 3.24%
Avg Daily Range (30 D):	$0.09 | 2.05%
Avg Daily Range (90 D):	$0.10 | 2.36%

Institutional Daily Volume
Avg Daily Volume:	1.22M
Avg Daily Volume (30 D):	2.23M
Avg Daily Volume (90 D):	1.67M

Trade Size
Avg Trade Size (Sh.):	211
Avg Trade Size (Sh.) (30 D):	152
Avg Trade Size (Sh.) (90 D):	142

Institutional Trades
Total Institutional Trades:	337
Avg Institutional Trade:	$1.53M
Avg Institutional Trade (30 D):	$1.45M
Avg Institutional Trade (90 D):	$1.24M
Avg Institutional Trade Volume:	.42M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.67M
Avg Closing Trade (30 D):	$1.37M
Avg Closing Trade (90 D):	$1.24M
Avg Closing Volume:	441.54K

News

Mar 5, 2026 @ 7:42 PM 9 Biotech Stocks Trading Far Below Fair Value With... Source: David Wagner

Mar 4, 2026 @ 1:14 PM Moderna's $950 Million Settlement Clears Legal Ove... Source: Vandana Singh

Feb 20, 2025 @ 8:22 AM Will Moderna Stock Drop to $25? 1 Wall Street Anal... Source: Eric Volkman

Jun 13, 2024 @ 9:12 AM Ultragenyx (RARE) Moves 7.8% Higher: Will This Str... Source: Zacks Equity Research

Jun 6, 2024 @ 3:15 PM Treatment with Arbutus’ Imdusiran and VTP-3... Source: Arbutus Biopharma Corporation

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.17	$-.01	$-.17
Diluted EPS	$-.17	$-.01	$-.17
Revenue	$14.08M	$1.05M	$14.08M
Gross Profit
Net Income / Loss	$-33.5M	$-3.76M	$-33.5M
Operating Income / Loss	$-38.16M	$-5.29M	$-38.16M
Cost of Revenue
Net Cash Flow	$-18.32M	$-4.4M	$-18.32M
PE Ratio

Splits
Nov 04, 2010	1:5